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Background: Secondary infections pose tremendous challenges in Coronavirus disease
2019 (COVID-19) treatment and are associated with higher mortality rates. Clinicians
face of the challenge of diagnosing viral infections because of low sensitivity of available
laboratory tests.
Case Presentation: A 66-year-old woman initially manifested fever and shortness
of breath. She was diagnosed as critically ill with COVID-19 using quantitative
reverse transcription PCR (RT-qPCR) and treated with antiviral therapy, ventilator and
extracorporeal membrane oxygenation (ECMO). However, after the condition was
relatively stabled for a few days, the patient deteriorated with fever, frequent cough,
increased airway secretions, and increased exudative lesions in the lower right lung
on chest X-rays, showing the possibility of a newly acquired infection, though sputum
bacterial and fungal cultures and smears showed negative results. Using metagenomic
next-generation sequencing (mNGS), we identified a reactivation of latent human herpes
virus type 1 (HHV-1) in the respiratory tract, blood and gastrointestinal tract, resulting in a
worsened clinical course in a critically ill COVID-19 patient on ECMO. Anti-HHV-1 therapy
guided by these sequencing results effectively decreased HHV-1 levels, and improved
the patient’s clinical condition. After 49 days on ECMO and 67 days on the ventilator, the
66-year-old patient recovered and was discharged.
Conclusions: This case report demonstrates the potential value of mNGS for
evidence-based treatment, and suggests that potential reactivation of latent viruses
should be considered in critically ill COVID-19 patients.
Keywords: COVID-19, HHV-1, metagenomic next-generation sequencing (mNGS), diagnosis, case report
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BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is the seventh known coronavirus that can infect humans
after HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1,
SARS-CoV, and MERS-CoV. The Coronavirus disease 2019
(COVID-19) global pandemic caused by SARS-CoV-2 has
affected 205,372,963 of the world’s population, with 4,334,178
total deaths, as of August 13, 2021 (https://coronavirus.jhu.
edu/map.html). The symptoms in the majority of patients
infected with SARS-CoV-2 have been relatively mild, but 10–15%
patients developed severe infections (1). Compared with patients
with mild symptoms, the severe patients are older, with more
comorbidities and lower lymphocyte counts (2, 3) and experience
higher mortality. Secondary infections or co-infections, mainly
by bacteria or viruses, occur in 10–30% of hospitalized COVID19 patients (4), contributing to the high incidence of severe
infection and mortality of COVID-19.
Human herpes virus type 1 (HHV-1) is a double stranded
DNA virus that infects a large population worldwide. According
to the conservative estimate, more than 90% of the human
adult population has latently infected by HHV-1 globally (5–8).
HHV-1 establishes latent infection within ganglial cells, of
which the trigeminal ganglia are the most commonly affected.
When the body’s immunity weakens, HHV-1 can be reactivated
and cause opportunistic infection. The mortality of influenza
patients is increased with concomitant HHV-1 infection, but
the pathogenesis remains unclear (9). Whether SARS-CoV-2
coinfected HSV may aggravate the condition of COVID-19 has
not been reported yet. We present a case of COVID-19 infection,
followed by HHV-1 reactivation that exacerbated the condition
of COVID-19.

FIGURE 1 | Representative images of the thoracic CT scans. Chest computed
tomograms showing multifocal bilateral ground glass opacities with patchy
consolidations, prominent in the peripheral distribution on day 4 after
symptom onset.

(RT-qPCR). The swab registered as positive for SARS-CoV-2
while antigen tests for influenza A and B registered negative.
Upon admission, arbidol for antiviral therapy (0.2 g, oral,
three times daily) and moxifloxacin for anti-bacterial therapy
(400 mg, intravenous drips, once a day) were implemented to
control patient’s rapidly deteriorating condition. On Day 2 of
hospitalization, the patient developed shortness of breath and
chest tightness, and required supplemental oxygen via oxymask
(oxygen flow at 10 L/min). Vitals included: respiratory rate
30–45 breaths per minute, oxygen saturation of 93–97% via
pulse oximetry, and arterial blood gas PO2 55 mmHg on mask
oxygen at 10 L/min. Non-invasive ventilator-assisted ventilation
was initiated.
On Day 3, the patient’s chest tightness and shortness of breath
persisted. Chest X-rays indicated a superimposed pneumonic
process. Hypoxemia showed no significant improvement
after increasing PEEP and oxygen concentration. Based on
the Extracorporeal Life Support Organization guidelines,
extracorporeal membrane oxygenation (ECMO) (V-V mode)
was initiated on Day 5. During this period, the patient’s vital
signs remained stable and SARS-CoV-2 viral copy number in NP
samples continued to decrease (Figure 2).
On Day 14, the patient developed a frequent productive
cough, and pulse oxygen saturation dropped to 88%,
accompanied by increased heart rate (117 beats per minute),
breathing rate (42 breaths per minute), and a temperature of
37.8◦ C. A small amount of light blood fluid was suctioned
out of the endotracheal tube. Chest X-rays showed increased
exudative lesions in the lower right lung. The white blood
cell count increased to 18.39 × 109 cells/L (reference range
3.5–9.5 × 109 cells/L). Blood procalcitonin was negative, and
sputum bacterial and fungal cultures and smears were negative,
raising the possibility of a newly acquired infection, but with
unknown etiology.

CASE PRESENTATION
A 66-year-old woman presented to the First Affiliated Hospital
of Xi’an Jiaotong University on February 5, 2020, with a
4-day history of fever and shortness of breath. Apart from
hypertension, the patient had no other underlying medical
conditions. Laboratory tests were unremarkable except for a low
lymphocyte count of 0.72 × 109 cells/L (reference range 1.1–3.2
× 109 cells/L) and high C-reactive protein of 71 mg/L (reference
range 0-10 mg/L). The respiratory rate was 30 breaths/min, and
oxygen saturation was 83% on ambient air. Chest computed
tomography (CT) showed multifocal bilateral ground glass
opacities (GGO) with patchy consolidations, prominent in the
peripheral distribution and predilected to the posterior and
lower lobes (Figure 1). Given a history of having contact with
a confirmed COVID-19 patient and characteristic changes on
CT imaging, a nasopharyngeal swab (NP) specimen was sent for
SARS-CoV-2 testing by quantitative reverse transcription PCR
Abbreviations: COVID-19, Coronavirus disease 2019; HHV-1, Human herpes
virus type 1; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; CT,
Computed tomography; NP, nasopharyngeal swab; RT-qPCR, Quantitative reverse
transcription PCR; ECMO, Extracorporeal membrane oxygenation; mNGS,
Metagenomic next-generation sequencing.
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FIGURE 2 | Cycle threshold value of SARS-CoV-2. Blue: Nasopharyngeal swab. Red: Sputum.

X-ray showed the lesions in the lower right lung were no
longer visible.
In subsequent days, the patient’s clinical symptoms continued
to improve, SARS-CoV-2 tests in sputum and NP maintained
negative, and mNGS revealed no HHV-1 reads in sputum and
blood. After 49 days on ECMO (February 9th-March 28th) and
67 days on the ventilator (February 6th-April 13th), the patient
recovered and was finally discharged.

DISCUSSION AND CONCLUSIONS
To the best of our knowledge, this is the first report describing
re-activation of latent HHV-1 in a critically ill COVID-19 patient
with prolonged ECMO support. HHV-1 is a double stranded
DNA virus of genus Simplexvirus, family Herpesviridae. HHV-1
commonly resides in sensory ganglia in latency. A variety of
stimuli such as stress, fever and immune suppression can trigger
lytic replication and result in production of infectious virus
(10). In an immune competent patient, HHV-1 infection is
mild and self-limiting. However, HHV-1 infection can be severe
and prolonged in immunocompromised individuals without
treatment, leading to significant morbidity and mortality (11).
In this report, the lymphocyte count of the patient decreased
significantly when admitted to the hospital for COVID-19
and during hospitalization. Lymphopenia is common in severe
COVID-19 patients (12). ECMO therapy is also associated
with a decrease of lymphocyte count and functionality (13).
Interestingly, CD8+ T cells play an essential role in preventing
HHV-1 reactivation (14). The lower levels of lymphocytes
in the reported patient might have permitted or promoted
the reactivation of HHV-1 virus (15). Anti-HHV-1 therapy
using acyclovir decreased HHV-1 load and alleviated the
patient’s clinical symptoms, indicating the significance of HHV1 infection in the COVID-19 patient. We don’t have direct
evidence of HHV-1 pneumonia, but the clinical scenario (mNGS
detection and the effect of anti HHV-1 treatment) is highly
suggestive of causation.
Our report calls for awareness of latent virus reactivation in
severe COVID-19 patients, particularly when infectious agents

FIGURE 3 | mNGS detection and anti HHV-1 therapy. Acyclovir: 0.5 g
intravenous every 8 h from Day 19 to Day 35.

To further identify the presence of any newly acquired
respiratory pathogens, PACEseq metagenomic next-generation
sequencing (mNGS) (Hugobiotech, Beijing) of sputum was
performed on Day 16 for pan-pathogen detection. The mNGS
report came out on Day 18 (48 h after inspection) and showed
that in addition to SARS-CoV-2 (9,266 reads/million), HHV1 (484 reads/million) was predominant in the sputum. Then,
mNGS re-examinations of samples including sputum, blood, NP,
lung lavage, and stomach fluid were performed immediately on
Day 18. The results showed the amount of HHV-1 in sputum
increased to 81,098 reads per million (RPM). HHV-1 was also
detected in blood (44 RPM), NP (89,833 RPM), lung lavage
(8 RPM) and stomach fluid (46 RPM), suggesting a latent
reactivation of HHV-1 (Figure 3). Guided by these sequencing
results, an anti HHV-1 agent, acyclovir (0.5 g, intravenous every
8 h), was initiated. After 14 days of anti-HHV-1 therapy, the
number of HHV-1 reads decreased and reached to single digit
level of RPM. The patient’s clinical condition improved, with
normal body temperature, heart rate (62 beats per minute),
breathing rate (15 breaths per minute), oxygen saturation of
97–100%, and white blood cell count (8.97× 109 cells/L). Chest
Frontiers in Medicine | www.frontiersin.org
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are unknown. Identification of latent virus activation becomes a
challenging task for the routine diagnostic tests if the causative
agents are unknown. Our report utilized mNGS technology,
which successfully detected HHV-1 DNA in multiple body sites,
and was valuable in monitoring the dynamics of viral loads over
treatment course.
mNGS is a new pan-pathogen detection technology, which
can theoretically detect all known pathogens including bacteria,
viruses, fungi, and parasites in one run, with unbiased results.
Compared to the conventional diagnostic methods, mNGS has
a higher sensitivity and specificity and costs less time. In this
case report, mNGS successfully detected HHV-1 in different
types of samples, including sputum, blood, NP, lung lavage, and
stomach fluid within 2 days, indicating significant advantages
in the diagnosis of pathogens, which contributes to a timely
treatment to the patient.
In conclusion, we present a case of COVID-19 with HHV-1,
followed by HHV-1 reactivation that exacerbated the condition of
COVID-19. mNGS was used for the rapid clinical diagnosis of the
pathogen, demonstrating the potential value of metagenomics
for evidence-based treatment. This case report suggests that
potential reactivation of latent viruses should be considered in
critically ill COVID-19 patients.
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